Harbeck, Nadia <br/><br/>
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Sep 2017 
 - 3046-3054 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2016.71.9815  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Ado-Trastuzumab Emtansine<br/>Adult<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Breast Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Maytansine--analogs & derivatives<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Precision Medicine--methods<br/>Prospective Studies<br/>Receptor, ErbB-2--biosynthesis<br/>Trastuzumab